share_log

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45

Benzinga ·  Nov 25, 2024 21:10  · Ratings

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $42 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment